tools_research.jpg
Research Our clients benefit from
industry knowledge and
M&A craftsmanship
gradient
Pharma manufacturing sites – an interactive map
We established an interactive map showing all manufacturing sites which are approved by FDA and /or EMA for manufacturing, analysis, packaging and distribution of pharmaceuticals (click on map to the right).

Approximately 24’000 sites are shown, double-counting sites which have EMA and FDA approval. FDA approvals count to 9’800 dots, the balance is by EMA. Sites can be selected by type governing body (FDA or EMA), type of approval (GMP or GDP for EMA; more granular for FDA), and keyword. Hovering the mouse over a dot shows the full details on record.

Data have been withdrawn in March 2017 from the www.fda.org and EMA’s EUDRA website, and were geocoded by KP using Google’s geocoding service.
Market Reports
What drives Mergers & Acquisitions in the Pharma industry?

The pharmaceutical industry probably sees more M&A activity than any other industry, both in the...

How to sell a pharma brand

Selling and buying established products has long been a standard part of the business development of...

The year in review 2016: Cooling down - or the calm before the storm?

M&A in the Pharma industry went through a cooling phase in 2016. After a very hectic phase in 2014...

Global Pharma/Biotech M&A Report 2016

For the Pharma and Biotech industry, the year 2015 can be summarized in just three phrases:...

Global Pharma/Biotech M&A Report 2015

The 2015 edition of the Global Pharma Biotech M&A Report features: A global overview about the...

Global Pharma & Biotech M&A Report 2014

The "Global Pharma & Biotech M&A Report 2014" highlights trends and strategic shifts in the global...

China: Sailing in Choppy Waters

Read in this report from InterChina Consulting (IMAP China) about crucial implications of China's...

M&A in China - A Corporate Survey by InterChina

M&A transactions in China are around 5% of global activity while two thirds of all transactions are...

Strategies for the China Oncology Market

This report from InterChina Consulting (IMAP China) provides insights and strategies for...

Global Pharma & Biotech M&A Report 2013

IMAP's Global Pharma & Biotech M&A Report 2013 contains regional reviews and highlights on M&A...

CEIBS 'Business in China' Survey 2013

This InterChina (IMAP China) report, based on a survey from CEIBS, documents the perceived business...

Investment Opportunities in China's Eldercare Industry

China's "aging society" offers interesting investment opportunities for the healthcare sector. This...

Vitamins, Minerals & Supplements: M&A Summary

Demand for VMS doesn't just come from consumers - corporates and private equity houses have been...

Global Pharma & Biotech M&A Report 2012

Review of 2011 M&A deals, including Gilead/Pharmasset: anatomy of a billion-dollar R&D deal. And:...

China: Diagnosis for Growth - Global Pharma Companies Face Layoffs

After 2006, global Pharma restructured their China businesses. Within just five years, the game has...

China: The Mixed Effects of Healthcare Reform in Rural Areas

InterChina Consulting (IMAP China) studied the effects of the healthcare reform in rural areas, and...

Healthcare Equipment & Supplies Global Report 2011

Whilst the global economic crisis and the reduction in healthcare expense reimbursement have had a...

China Healtchare System - a Phoenix from the Ashes

In April 2009, the government announced a RMB 850bn (USD 124bn) program to overhaul the...

China: A mistery for Big Pharma Companies

InterChina Consulting (IMAP China) interviewed William Keller, former Country Manager of Roche, to...

India: Fragmented Hospital Sector to Grow by 27% p.a.

The Indian hospital sector, currently worth USD 25bn, is anticipated to grow by 27% p.a., finds an...

China: The Healthcare System at a Turning Point

The release of the Healthcare reform plan in April 2009 marks a turning point in the long-neglected...